Literature DB >> 16198885

Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity.

Hua Yang1, Anna Woo, Daniel Monakier, Michal Jamorski, Katie Fedwick, E Douglas Wigle, Harry Rakowski.   

Abstract

BACKGROUND: Patients with hypertrophic cardiomyopathy and left atrial (LA) enlargement have increased morbidity and mortality. We analyzed the clinical and echocardiographic factors related to LA enlargement, particularly the degree of left ventricular (LV) hypertrophy and diastolic function.
METHODS: A total of 104 patients with hypertrophic cardiomyopathy (age 53 +/- 15 years, 64% men) were divided into two groups based on the indexed LA volume (LAVI) (mL/m2) measured by echocardiography: group A (or smaller LAVI group, n = 43) was defined as LAVI < or = 34 mL/m2; and group B (or larger LAVI group, n = 61) as LAVI > 34 mL/m2. Detailed clinical and echocardiographic data were obtained. LV wall thickness was measured at 15 sites at 3 levels (base, mid, and apex). Diastolic function was assessed from mitral and pulmonary venous inflow velocities and Doppler tissue imaging.
RESULTS: Both groups were similar in terms of sex, functional class (1.6 +/- 0.8 vs 1.5 +/- 0.8, group B vs A, P = .64), and incidence of atrial fibrillation (13% vs 5%, P = .19). However, patients of group B had a significantly higher incidence of serious cardiovascular events (16.4% vs 2.3%, group B vs A, P = .024). Both groups had a similar degree of resting LV outflow tract obstruction (19 +/- 30 vs 12 +/- 13 mm Hg, group B vs A, P = .06). However, those in group B had a higher incidence of at least moderate mitral regurgitation (25% vs 5%, group B vs A, P = .007), more LV hypertrophy at 6 LV nonapical wall segments (P < .05-P < .001), and a higher hypertrophy (Wigle) score (6.2 +/- 2.2 vs 4.5 +/- 2.1, group B vs A, P < .001). In addition, patients of group B had a higher incidence of abnormal diastolic filling (57% vs 28%, group B vs A, P = .003), a higher early diastolic velocity/early diastolic mitral annular velocity (10.2 +/- 4.9 vs 7.5 +/- 2.9, group B vs A, P = .003), and a higher calculated LA pressure (14.8 +/- 6.5 vs 11.1 +/- 3.4 mm Hg, group B vs A, P = .0011).
CONCLUSIONS: Patients with hypertrophic cardiomyopathy and LA enlargement had more serious cardiovascular events and demonstrated greater LV hypertrophy, more diastolic dysfunction, and higher filling pressures.

Entities:  

Mesh:

Year:  2005        PMID: 16198885     DOI: 10.1016/j.echo.2005.06.011

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  25 in total

1.  Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction.

Authors:  Yinsu Zhu; Eun-Ah Park; Whal Lee; Hyung-Kwan Kim; Ajung Chu; Jin Wook Chung; Jae Hyung Park
Journal:  Eur Radiol       Date:  2015-01-18       Impact factor: 5.315

Review 2.  Apical variant hypertrophic cardiomyopathy "multimodality imaging evaluation".

Authors:  Gary Huang; Shaimaa A Fadl; Stan Sukhotski; Manuela Matesan
Journal:  Int J Cardiovasc Imaging       Date:  2019-12-18       Impact factor: 2.357

3.  Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients.

Authors:  Philippe Debonnaire; Joep Thijssen; Darryl P Leong; Emer Joyce; Spyridon Katsanos; Georgette E Hoogslag; Martin J Schalij; Douwe E Atsma; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Int J Cardiovasc Imaging       Date:  2014-02-06       Impact factor: 2.357

4.  Three-dimensional speckle tracking echocardiography for the preclinical diagnosis of hypertrophic cardiomyopathy.

Authors:  Mohamed F A Aly; Wessel P Brouwer; Sebastiaan A Kleijn; Albert C van Rossum; Otto Kamp
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-30       Impact factor: 2.357

Review 5.  Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.

Authors:  Waseem Hindieh; Raymond Chan; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

Review 6.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

Review 7.  Contemporary narrative review on left atrial strain mechanics in echocardiography: cardiomyopathy, valvular heart disease and beyond.

Authors:  Vardhmaan Jain; Raktim Ghosh; Manasvi Gupta; Yoshihito Saijo; Agam Bansal; Medhat Farwati; Rachel Marcus; Allan Klein; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

8.  Usefulness of left atrial volume index to predict heart failure hospitalization and mortality in ambulatory patients with coronary heart disease and comparison to left ventricular ejection fraction (from the Heart and Soul Study).

Authors:  Bryan Ristow; Sadia Ali; Mary A Whooley; Nelson B Schiller
Journal:  Am J Cardiol       Date:  2008-05-09       Impact factor: 2.778

9.  Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology.

Authors:  S C Menon; V V Michels; P A Pellikka; J D Ballew; M L Karst; K J Herron; S M Nelson; R J Rodeheffer; T M Olson
Journal:  Clin Genet       Date:  2008-07-21       Impact factor: 4.438

Review 10.  Predictors of Atrial Fibrillation Risk in Hypertrophic Cardiomyopathy.

Authors:  Kamil Tuluce; Selcen Yakar Tuluce
Journal:  J Atr Fibrillation       Date:  2015-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.